Hoth continues to advance HT-001 in its Phase 2 CLEER-001 clinical trial targeting EGFR-inhibitor–associated rash, a significant unmet need in oncology supportive care. Recent progress includes: ...
Investing.com -- Hoth Therapeutics Inc (NASDAQ:HOTH) stock rose 4% on Wednesday after the clinical-stage biopharmaceutical company provided an update on its therapeutic pipeline, highlighting progress ...
It’s the final stretch of 2025, and Star Wars: The Old Republic is rolling out a fully loaded month of events — celebrations, pirates, snowballs, ancient Gree technology, anniversary freebies, and yes ...
Advocates for transparency on social media cheered this weekend when X, the app owned by tech billionaire Elon Musk, rolled out a new feature that disclosed what the company said were the country ...
Hoth Therapeutics (HOTH) has been officially accepted into the Nvidia (NVDA) Connect Program, a global initiative supporting innovative software and technology companies working with advanced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results